Skip to main content

ValiRx news round-up: March 2024

9 Apr 2024


This news round-up covers our updates from March, including highlights from Inaphaea, our attendance at the flagship industry event BioEurope Spring, and a major evaluation agreement signed with Imperial College London. 


Initiation of evaluation project agreement with Imperial College London 

We were delighted to announce the signature of an evaluation agreement with Imperial College London. This agreement enables ValiRx to evaluate research relating to novel therapeutic candidates for cancer treatment. 
The agreement specifically focuses on investigating a lead series of dual-kinase inhibitor candidates that show promise in reversing resistance to the current standard of care therapeutics in ovarian and other types of cancer. Importantly, a similar approach has already been validated in clinical studies with other assets across a range of tumour types and it holds significant potential as a novel combination treatment. 
Find out more in our video with BRR Media, here. 

BioEurope Spring 

ValiRx’s Mark Treharne and Inaphaea’s Dr Andrew Carnegie were pleased to attend EBD Group’s BioEurope Spring between 18 and 20 March in Barcelona. Supporting One Nucleus’ stand, the team had an incredibly productive time, meeting with delegates in the dedicated one to one sessions and listening to insights from the keynote speakers. 

Meet the Inaphaea commercial team 

Whilst ValiRx’s subsidiary Inaphaea BioLabs is led by science, it is backed by deep commercial understanding, and the team appreciates the challenges faced by drug developers. This is thanks to the strength of Inaphaea’s commercial team which combines business acumen and experience with scientific expertise. 

In this blog, meet Inaphaea’s commercial team and find out what they have to say about the company’s ongoing growth and development. 

Partnerships and PDCs  

In the second instalment of Inaphaea’s three-part video series, the team explores how it works with its expert collaborators. Check it out here. 

Thanks to Inaphaea’s collaborators for their input: 

  • Steve Trim, CSO at Venomtech Ltd 
  • Professor Claire Thompson, Founder and CEO of Agility Life Sciences 
  • Peter De'Ath, Head of Client Management at HistologiX 
  • Dr Mark Eccleston, Managing Director at OncoLytika 
  • Natassja Bush, Managing Director at Inspiralis Limited 

The third and final video of the series explains how Inaphaea’s patient-derived cells are used in drug discovery for its clients. You can also hear from Inaphaea’s collaborators as they share their thoughts on PDCs. Watch the video here. 


News roundup